View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 26, 2020

Avalon GloboCare to develop intranasal and oral Covid-19 vaccine

US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine against Covid-19 for intranasal or oral administration.

US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine against Covid-19 for intranasal or oral administration.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection, which is responsible for morbidity and can lead to death.

Avalon GloboCare noted that the vaccine candidate is a fusion of an S-layer viral particle mimic and the SARS-CoV-2 spike protein, said to facilitate ease of manufacturing and delivery.

On contrary to a needle-based injection given into the muscle or under the skin, this vaccine is meant for non-invasive delivery through the nasal or oral passageways.

The vaccine could decrease the severity of Covid-19 by preventing the more harsh respiratory inflammation and organ damage, as well as build immunity against the SARS-CoV-2 virus that causes the disease.

As part of the collaboration, Avalon’s expertise and bio-manufacturing infrastructure and clinical study implementation resources will be leveraged along with BOKU professors scientific capabilities and laboratory expertise.

BOKU professors have already created the approaches required to synthesise conjugate vaccines with an S-layer artificial viral envelope linked to a viral antigen.

As proof of concept, the researchers demonstrated that these types of protein conjugate vaccine candidates could induce immune-protective antibody responses.

Avalon GloboCare president and CEO David Jin said: “We are working swiftly and diligently with BOKU to complete the laboratory testing and characterisation of the S-layer fusion protein SARS-CoV-2 vaccine candidate.

“We believe that our novel vaccine approach has the potential to be effective. Importantly, this vaccine candidate could be manufactured and delivered more rapidly compared to traditional vaccines, providing access and immunisation to a larger population of people around the globe to help combat the Covid-19 pandemic.”

The research for Covid-19 vaccine candidate is part of an existing partnership between Avalon and BOKU to leverage S-layer technology for other respiratory infection vaccine programmes, including influenza.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology